Why the study?
Copeptin is secreted early in AMI, but whether copeptin combined with cTnI and a nondiagnostic ECG allows ruling out AMI at presentation was unknown.
Does adding copeptin to cardiac troponin I improve the early rule-out of acute myocardial infarction in patients presenting to the emergency department with chest pain within 6 hours of onset?
Does adding copeptin to cardiac troponin I improve the early rule-out of acute myocardial infarction in patients presenting to the emergency department with chest pain within 6 hours of onset?
Adding copeptin to sensitive cardiac troponin I allows for the safe and rapid rule-out of acute myocardial infarction in over half of emergency department patients presenting with early chest pain.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for early AMI rule-out with copeptin plus troponin in ED; leaves open validation in randomized trials before adoption.
OBJECTIVES: The goal of this study was to demonstrate that copeptin levels <14 pmol/L allow ruling out acute myocardial infarction (AMI) when used in combination with cardiac troponin I (cTnI) <99 th percentile and a nondiagnostic electrocardiogram at the time of presentation to the emergency department (ED). BACKGROUND: Copeptin is secreted from the pituitary early in the course of AMI. METHODS: This was a 16-site study in 1,967 patients with chest pain presenting to an ED within 6 hours of pain onset. Baseline demographic characteristics and clinical data were collected prospectively. Copeptin levels and a contemporary sensitive cTnI (99 th percentile 40 ng/l; 10% coefficient of variation 0.03 μg/l) were measured in a core laboratory. Patients were followed up for 180 days. The primary outcome was diagnosis of AMI. Final diagnoses were adjudicated by 2 independent cardiologists blinded to copeptin results. RESULTS: AMI was the final diagnosis in 156 patients (7.9%). A negative copeptin and cTnI at baseline ruled out AMI for 58% of patients, with a negative predictive value of 99.2% (95% confidence interval: 98.5 to 99.6). AMIs not detected by the initial cTnI alone were picked up with copeptin >14 pmol/l in 23 (72%) of 32 patients. Non-ST-segment elevation myocardial infarctions undetected by cTnI at 0 h were detected with copeptin >14 pmol/l in 10 (53%) of 19 patients. Projected average time-to-decision could be reduced by 43% (from 3.0 h to 1.8 h) by the early rule out of 58% of patients. Both abnormal copeptin and cTnI were predictors of death at 180 days (p < 0.0001 for both; c index 0.784 and 0.800, respectively). Both were independent of age and each other and provided additional predictive value (all p < 0.0001). CONCLUSIONS: Adding copeptin to cTnI allowed safe rule out of AMI with a negative predictive value >99% in patients presenting with suspected acute coronary syndromes. This combination has the potential to rule out AMI in 58% of patients without serial blood draws.
No takes yet. Share an insight, caveat, or question.
Maisel et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: